To the annoyance of some shareholders, Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) shares are down a considerable 27...
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Pieris Pharmaceuticals (PIRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.